Indeed, oral antidiabetics, such as thiazolidinediones and intranasal insulin have shown differential efficacy in AD depending on the APOE-ε4 genotype [37], which is the strongest common genetic risk factor for late-onset AD [38]. Here, APOE is linked to Alzheimer disease.